Related Experiment Videos
[Hormone replacement therapy and cardiovascular diseases: different populations, different risks]
S Panico1, R Galasso, E Celentano
1Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi Federico II, Napoli.
Annali Dell'Istituto Superiore Di Sanita
|January 1, 1997
Summary
Oral hormone replacement therapy (HRT) may reduce coronary risk in menopause. However, large-scale use warrants caution due to potential excess mortality, especially where heart disease is less common than breast cancer before age 60.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Public Health
Context:
- Observational studies suggest oral hormone replacement therapy (HRT) is linked to a 20-40% reduction in coronary heart disease risk among menopausal women.
- Population-based analyses highlight potential risks, including excess mortality, particularly in regions where breast cancer incidence precedes coronary heart disease before age 60.
Purpose:
- To analyze the risk-benefit profile of oral hormone replacement therapy (HRT) in menopause.
- To evaluate the impact of HRT on mortality trends, considering disease prevalence variations across populations.
Summary:
- While HRT shows a reduction in coronary risk, large-scale HRT use may lead to increased mortality, especially in specific demographic groups.
- Mortality trends in coronary heart disease suggest a need for caution regarding widespread HRT adoption, even in populations where a relative benefit is currently estimated.
Impact:
- Findings suggest a need for careful consideration of HRT's long-term effects on mortality.
- Highlights the importance of population-specific risk-benefit assessments for HRT in menopausal women.
- Informs clinical guidelines and public health strategies regarding HRT use and its cardiovascular implications.